TY - CHAP M1 - Book, Section TI - Cellular Therapy for Lymphoma A1 - Ahmed, Sairah A1 - Parmar, Simrit A1 - Neelapu, Sattva A2 - Kantarjian, Hagop M. A2 - Wolff, Robert A. A2 - Rieber, Alyssa G. Y1 - 2022 N1 - T2 - The MD Anderson Manual of Medical Oncology, 4e AB - KEY CONCEPTSAdoptive cellular immunotherapy with chimeric antigen receptor (CAR) T-cell therapy has changed the treatment landscape of B-cell non-Hodgkin lymphoma (NHL), especially for aggressive B-cell lymphomas.CAR T-cell therapy is FDA approved for poor-risk diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) when no other effective treatment options are available, and it has shown long-term remissions in up to 40% of patients without other treatment options.CAR T-cell–related toxicities remain important potential complications of this therapy, which includes acute toxicity with cytokine-release syndrome and neurotoxicity, as well as long-term complications such as infection and cytopenias.Relapse after CAR T-cell therapy remains a significant challenge and, although the exact mechanisms causing tumor escape remain unknown, relapse after CAR T-cell therapy that targets the CD19 antigen can be categorized broadly as (1) antigen loss, (2) lack of CAR T-cell persistence, or (3) host-specific factors.Real-world analyses highlight that patient response rates and toxicity profiles were similar to the pivotal trials, while being inclusive of patients who would not fit within the highly restrictive parameters of clinical trials.Trials are ongoing in multiple lymphoma histologies including T-cell lymphoma and Hodgkin lymphoma, in addition to novel autologous CAR constructs and allogeneic CAR T and natural killer (NK) cells. SN - PB - McGraw Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1190833793 ER -